Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 29.
doi: 10.1007/s13555-025-01546-4. Online ahead of print.

The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review

Hussein Abdel Dayem  1 , Anwar Al Hammadi  2 , Ashraf Reda  3 , Fatima Albreiki  4 , Ayman Al Naeem  5 , Ahmed Ameen  6 , Mohamed Ahmed  7 , Huda Rajab Ali  8 , Mohamed Elrayes  9 , Gozde Senay  9 , Muna Al Murrawi  10
Affiliations
Review

The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review

Hussein Abdel Dayem et al. Dermatol Ther (Heidelb). .

Abstract

Alopecia areata is an inflammatory autoimmune disease that presents as non-scarring hair loss in adults and children and causes substantial psychological distress, economic burden, and reduced quality of life for those affected. Although steroids and immunosuppressants are common treatments for alopecia areata, results from studies of Janus kinase inhibitors in the systemic management of alopecia areata, including those from long-term efficacy and safety studies on the Janus kinase 1/2 inhibitor baricitinib, show promising results. Despite alopecia areata placing a burden on healthcare systems in the Middle East, published data on the overall prevalence, patient characteristics, and treatment landscape for alopecia areata across the region are sparse, and a lack of approved therapies and insufficient access to treatment are treatment obstacles. Herein, we describe the burden of alopecia areata on patients and healthcare systems, review publications from the United Arab Emirates (UAE) on alopecia areata, highlight gaps in the data, and review clinical trial publications on the management of alopecia areata with baricitinib, the first Janus kinase inhibitor approved for the treatment of alopecia areata in the UAE. A regional expert assessment of the burden of alopecia areata and unmet medical needs in the UAE is provided, along with an expert opinion on treating patients with severe alopecia areata.

Keywords: Alopecia areata; Janus kinase (JAK) inhibitor; Middle East; United Arab Emirates.

Plain language summary

Alopecia areata is a disease in which the immune system attacks healthy hair follicles, leading to hair loss. It occurs in both adults and children and can have a negative effect on mental health, cause financial worries, and lead to a reduced quality of life. For Middle Eastern countries, including the United Arab Emirates, there is a lack of published data that specifically describe the number of people affected by alopecia areata in the region, their features and medical needs, and the treatment options available to them. Several medications are licensed for the treatment of alopecia areata, including steroids, creams, and a group of medications called Janus kinase inhibitors. Baricitinib is a Janus kinase inhibitor. Even though baricitinib is approved for severe alopecia areata and expert dermatologists use it to successfully treat alopecia areata, the costs of Janus kinase inhibitors cannot be reimbursed for many patients in need globally, including many countries in the Middle East. This is because alopecia areata is not recognised as a dermatological immunological disease. This article highlights the need for more data from the Middle East and United Arab Emirates to support patients with alopecia areata to access the treatment they need to manage their condition.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: Hussein Abdel Dayem has received honoraria from AbbVie, Eli Lilly and Company, Johnson & Johnson, Leo, Novartis, and Pfizer. Ayman Al Naeem is a board member at Emirates Dermatology Society. Ahmed Ameen has received payment or honoraria for lectures, presentations, speakers bureaus, abstract (and subsequent poster) writing, or educational events from AbbVie, Eli Lilly and Company, Janssen, Leo, Pfizer, and Sanofi. Mohamed Elrayes and Gozde Senay are employees of and minor stakeholders in Eli Lilly and Company. Anwar Al Hammadi, Ashraf Reda, Fatima Albreiki, Huda Rajab Ali, Mohamed Ahmed and Muna Al Murrawi have nothing to disclose. Ethical Approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

References

    1. Al Hammadi A, Parmar NV, Aljefri K, et al. Review on alopecia areata in the Middle East and Africa: landscape and unmet needs. Dermatol Ther. 2023;13:1435–64. https://doi.org/10.1007/s13555-023-00946-8 . - DOI
    1. Muntyanu A, Gabrielli S, Donovan J, et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol. 2023. https://doi.org/10.1111/jdv.18926 . - DOI - PubMed
    1. Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82:675–82. https://doi.org/10.1016/j.jaad.2019.08.032 . - DOI - PubMed
    1. Goh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006;20:1055–60. https://doi.org/10.1111/j.1468-3083.2006.01676.x . - DOI - PubMed
    1. Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol. 2018;79:556-8.e1. https://doi.org/10.1016/j.jaad.2018.01.048 . - DOI - PubMed

LinkOut - more resources